A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients
A phase 3 trial of Docetaxel in triple-negative breast cancer, run by Jina Pharmaceuticals Inc., now recruiting.
Overview
A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients is a phase 3 interventional study registered as NCT03671044 by Jina Pharmaceuticals Inc., with 657 participants planned, started 2018-07-10 and due to reach its primary completion in 2025-05-31. Interventions recorded: Nanosomal Docetaxel Lipid Suspension (75 mg/m2), Nanosomal Docetaxel Lipid Suspension (100 mg/m2) and Taxotere® (100 mg/m2).
Similar pages
not linked directly; found by shared links- TrialA Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
Shares Docetaxel and the tag pipeline.
- TrialProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer
Shares Triple-negative breast cancer (TNBC) and the tag pipeline.
- TrialA Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer
Shares Triple-negative breast cancer (TNBC) and the tag pipeline.
- TrialPersonalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast Cancer
Shares Triple-negative breast cancer (TNBC) and the tag pipeline.
- TrialNuvastatic® Phase III Trial for Fatigue in Triple-Negative Breast Cancer
Shares Triple-negative breast cancer (TNBC) and the tag pipeline.
- TrialA Study to Evaluate the Safety and Efficacy of NDV-01 in Participants With NMIBC
Shares Docetaxel and the tag pipeline.
- TrialA Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment
Shares Docetaxel and the tag pipeline.
- TrialA Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Urothelial Carcinoma(PANKU-Bladder01)
Shares Docetaxel and the tag pipeline.